Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
AVEO Pharmaceuticals, Inc.
Alliance for Clinical Trials in Oncology
PDS Biotechnology Corp.
NRG Oncology
Fudan University
Groupe Oncologie Radiotherapie Tete et Cou
Merus B.V.
Gustave Roussy, Cancer Campus, Grand Paris
Merck Sharp & Dohme LLC
Merus B.V.
AstraZeneca
Johnson & Johnson Enterprise Innovation Inc.
Merck Sharp & Dohme LLC
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Universität des Saarlandes
Eastern Cooperative Oncology Group
R-Pharm
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Sun Yat-sen University
Radiation Therapy Oncology Group
Shandong Cancer Hospital and Institute
Radiation Therapy Oncology Group
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Brown University
University of Pittsburgh
Incyte Corporation
Radboud University Medical Center
Rakuten Medical, Inc.
EMD Serono
Centre Antoine Lacassagne
GlaxoSmithKline
Groupe Oncologie Radiotherapie Tete et Cou
Sun Yat-sen University
Groupe Oncologie Radiotherapie Tete et Cou
Fudan University
Groupe Oncologie Radiotherapie Tete et Cou
Groupe Oncologie Radiotherapie Tete et Cou
Groupe Oncologie Radiotherapie Tete et Cou
Huashan Hospital
Rakuten Medical, Inc.
Akeso
UNICANCER
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University